Want to see BMRA full AI Analyst Report?
BMRA Stock Chart & Stats
$2.88
-$0.02(-5.81%)
At close: 4:00 PM EST
$2.88
-$0.02(-5.81%)
Day’s Range― - ―
52-Week Range$1.73 - $4.60
Previous CloseN/A
Volume74.49K
Average Volume (3M)190.48K
Market Cap
$5.41M
Enterprise Value$4.94M
Total Cash (Recent Filing)$1.34M
Total Debt (Recent Filing)$193.00K
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding3,090,269
10 Day Avg. Volume453,881
30 Day Avg. Volume190,481
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.71
Price to Sales (P/S)1.32
P/FCF Ratio-1.81
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue1.14
Enterprise Value/Gross Profit26.44
Enterprise Value/Ebitda-1.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low recorded debt provides structural financial flexibility and reduces near-term solvency and refinancing risk. With limited interest burden the company can prioritize extending runway or funding commercialization, which is valuable given ongoing operating losses.
Established Diagnostics Sales ModelA product-driven business selling diagnostic kits through direct and distributor channels provides recurring order potential and geographic reach. This multi-channel commercial model can support steadier revenue capture over time if product-market fit and commercial execution improve.
Narrowing Losses / Improving BurnSequential improvement in operating losses and a reduction in cash burn indicate management has begun to rein in costs or stabilize revenue drivers. Sustained improvement would extend runway and lower near-term financing needs, making the operational trend a meaningful structural positive.
Bears Say
Declining Revenue & Tiny Gross MarginSteep top-line decline paired with a very low gross margin undermines scalability and pricing power. With only ~4% gross margin, the business cannot cover fixed operating costs at current volumes, making sustainable profitability dependent on new higher-margin products or substantial volume gains.
Persistent Negative Cash FlowConsistent operating cash burn creates structural reliance on external financing. Negative OCF erodes reserves and limits reinvestment capacity, increasing dilution risk and constraining the company's ability to fund commercialization or R&D without materially improving margins or revenue.
Shrinking Equity & Reliance On Related-party FundingMaterial decline in equity alongside reliance on a CEO-affiliated $500k advance signals increasing funding and governance risk. Using related-party advances to bridge liquidity is a structural vulnerability if access to independent capital markets remains constrained.
Biomerica News
BMRA FAQ
What was Biomerica Inc’s price range in the past 12 months?
Biomerica Inc lowest stock price was $1.73 and its highest was $4.60 in the past 12 months.
What is Biomerica Inc’s market cap?
Biomerica Inc’s market cap is $5.41M.
When is Biomerica Inc’s upcoming earnings report date?
Biomerica Inc’s upcoming earnings report date is Aug 27, 2026 which is in 54 days.
How were Biomerica Inc’s earnings last quarter?
Biomerica Inc released its earnings results on Apr 13, 2026. The company reported -$0.436 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.436.
Is Biomerica Inc overvalued?
According to Wall Street analysts Biomerica Inc’s price is currently Overvalued.
Does Biomerica Inc pay dividends?
Biomerica Inc does not currently pay dividends.
What is Biomerica Inc’s EPS estimate?
Biomerica Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomerica Inc have?
Biomerica Inc has 3,090,269 shares outstanding.
What happened to Biomerica Inc’s price movement after its last earnings report?
Biomerica Inc reported an EPS of -$0.436 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.962%.
Which hedge fund is a major shareholder of Biomerica Inc?
Currently, no hedge funds are holding shares in BMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biomerica Inc
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Technical Analysis
Strata Skin Sciences
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
―
Ownership Overview
13.18% Insiders
6.66% Mutual Funds
0.03% Other Institutional Investors
79.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---